Literature DB >> 25647614

Concerns about the off-licence use of amiodarone for Ebola.

Ankur Gupta-Wright1, James Lavers2, Sharon Irvine3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25647614     DOI： 10.1136/bmj.h272

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.

Authors:  Nahid Bhadelia; Lauren Sauer; Theodore J Cieslak; Richard T Davey; Susan McLellan; Timothy M Uyeki; Mark G Kortepeter
Journal:  Health Secur       Date:  2019-02-06

Review 2.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

Review 3.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 4.  Antiviral activity of cationic amphiphilic drugs.

Authors:  Cristiano Salata; Arianna Calistri; Cristina Parolin; Aldo Baritussio; Giorgio Palù
Journal:  Expert Rev Anti Infect Ther       Date:  2017-03-20       Impact factor: 5.091

Review 5.  Crimean-Congo haemorrhagic fever virus: Past, present and future insights for animal modelling and medical countermeasures.

Authors:  E J Mendoza; B Warner; D Safronetz; C Ranadheera
Journal:  Zoonoses Public Health       Date:  2018-04-20       Impact factor: 2.702

Review 6.  Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?

Authors:  José Miguel Vela
Journal:  Front Pharmacol       Date:  2020-11-09       Impact factor: 5.810

7.  Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein.

Authors:  Julie Huiyuan Xiao; Pramila Rijal; Lisa Schimanski; Arun Kumar Tharkeshwar; Edward Wright; Wim Annaert; Alain Townsend
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.